Floatz logo

Carboplatin

Malignant Pericardial Effusion

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Malignant Pericardial Effusion cohort.

Asset / SponsorPhaseRating
Recombinant Interleukin-12
National Cancer Institute (NCI)
Phase 1CC
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 1CC
Abi-007
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →